Previous 10 | Next 10 |
OVID stock is one of the biggest penny stock gainers in the biotech sector this week after Ovid Therapeutics Inc (NASDAQ:OVID) reported preliminary results from a Phase 2 open-label extension study. Positive Momentum Ovid Therapeutics has been one of the more interesting companies in th...
Gainers: Ovid Therapeutics (NASDAQ: OVID ) +27% . VolitionRx Limited (NYSEMKT: VNRX ) +24% . Cellcom Israel (NYSE: CEL ) +21% . Wheeler Real Estate Investment Trust (NASDAQ: WHLR ) +19% . Fresh Del Monte Produce (NYSE: FDP ) +16% . New Age Beverages Corporation (NASDAQ: NBEV ) ...
Thinly traded nano cap Ovid Therapeutics ( OVID +6.7% ) is up on below-average volume on the heels of preliminary results from a Phase 2 open-label extension study evaluating soticlestat (OV925/TAK-935) in patients with rare developmental and epileptic encephalopathies, including Drave...
Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare Epilepsies; Initial Data from Phase 2 ARCADE Trial Anticipated in Q1 ...
"Miracles are like pimples, because once you start looking for them, you find more than you ever dreamed you'd see ." - Lemony Snicket, The Lump of Coal Today we take a look a developmental biotech concern that is deep in "Busted IPO" territory. However, if things fall right for the compa...
The first patient has been randomized in a Phase 3 clinical trial, NEPTUNE, evaluating Ovid Therapeutics' ( OVID -3.2% ) lead candidate OV101 (gaboxadol) in patients with an inherited nervous system disorder called Angelman syndrome . More news on: Ovid Therapeutics Inc., Healthcare s...
NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the first patient has been randomized in the company...
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremey Levin, DPhil, MB, BChir, Chairman and Chief Exec...
Gainers: OpGen (NASDAQ: OPGN ) +79% . Marinus Pharmaceuticals (NASDAQ: MRNS ) +35% . Top Ships (NASDAQ: TOPS ) +25% . Natuzzi S.p.A. (NYSE: NTZ ) +23% . Mereo BioPharma Group (NASDAQ: MREO ) +23% . Ovid Therapeutics (NASDAQ: OVID ) +19% . Owens & Minor (NYSE: OMI ) +19% . ...
OpGen (NASDAQ: OPGN ) +77% to merge with Curetis N.V. More news on: OpGen, Inc., Top Ships Inc., The Michaels Companies, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...